Genentech, Inc.
NEWS
Suliman anticipates filing an Investigational New Drug application with the FDA for the PCD asset this year, and next year filing one for the cystic fibrosis asset.
AstraZeneca has been struggling to find an effective use for its anti-CTLA-4 antibody tremelimumab. It may have finally found it.
BioSpace is marking Martin Luther King, Jr. Day by sharing some of our recent coverage about what the life sciences industry is doing to address racial inequality.
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
When 2022 rolls around in a little more than a week, some Genentech employees will begin the new year in search of a new job.
On December 28, the U.S. Food and Drug Administration reported there had been 50 novel drug approvals for the year, and that was just for new chemical entities.
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
Mythic Therapeutics has roared out of the gate with a $103 million Series B financing round that will support “safer and smarter” next generation of antibody-drug conjugates (ADCs).
Several life sciences companies and life science-focused real estate firms have announced expansion plans as 2021 comes to an end.
JOBS
IN THE PRESS